S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer

Inclusion Criteria: * Histologic proof of primary squamous cell or adenocarcinoma of the esophagus * Locoregionally advanced carcinoma of esophagus without systemic metastases * Zubrod Performance Status 0-1; * Patients ≥ 18 years of age; * No hypersensitivity to E. coli -derived products; * AGC ≥ 1500/mm3, platelets ≥ 150,000/mm3, Hgb ≥ 10 gm%, serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 65 cc/min; serum calcium ≤ 11gm/dl; * Patients with prior malignancy are eligible if curable non-melanoma skin cancer or cervical cancer in situ or disease free ≥ 5 years; * No prior chest or upper abdomen radiotherapy; no prior systemic chemotherapy within the past 5 years; no prior esophageal or gastric surgery; * Written informed consent. Exclusion Criteria: * Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi. * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible). * Prior systemic chemotherapy or radiation therapy for esophageal cancer